Medtronic’s bone grafting product launched in Japan

Having received approval from Japan’s PMDA in 2018, Medtronic has now launched its Grafton demineralized bone matrix bone grafting product in Japan. The company said that the Grafton DBM, a bone graft extender, bone graft substitute and bone void filler, intended for use in bony voids or gaps in the skeletal system, is comprised of multiple forms, and that it is launching the Grafton Putty, Grafton Matrix and Grafton Strip in Japan. It claims the Grafton DBM is the first and only demineralized bone matrix product available in Japan, and that it has consistently high osteoconductivity scores and that it is the “most utilized and scientifically-studied DBM on the market.”
Jacob Paul, SVP and President, Spine and Biologics at Medtronic, said: “Our unmatched combination of biologic therapies, services and expertise help surgeons meet the needs of each unique patient. Grafton is an important option within our comprehensive, market-leading biologics portfolio, and we’re excited that surgeons in Japan now have access to this clinically-proven osteoinductive bone graft product.”